2Hurwitz H,Fehrenbacher L, Novotony W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer[J]. N Engl J Med,2004,350(23) :2335
3Giantonio BJ, Catalano PJ, Meropol NJ, et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer. Results from the Eastern Cooperative Oncology Group (ECOG) study E3200 [ J ]. Pro Am Soc Clin Oncol, 2005,23 : Is Abstr2
5Anton Ian L,Zhang H, Yang C,et al. Biotransformation of the anti-angiogenic compound SU5416 [ J ]. Drug Metab Dispos, 2000,28(12) :1505- 1512
6Hoekman K. SU6668, a multitargeted angiogenesis inhibitor [ J ].Cancer J ,2001,7(Suppl 3) :S134 - S138
7Rosell R, Fossella F, Milas L. Molecular markers and targeted therapy with novel agents: prospects in the treatment of non-small cell lung cancer[J]. Lung Cancer,2002,38(l Suppl) :43 - 49
8Hollywood E. Clinical issues in the administration of an anti-epidermal growth factor receptor monoclonal antibody, IMC- C225[J].Semin Oncol Nuts,2002,18(2 Suppl 2):30 - 35
9Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer[J]. N Engl J Med,2004,351(4) :337 - 345
2Giantonio BJ,Catalano PJ,Meropol NJ,et al.High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer:Results from the Eastern Cooperative Oncology Group (ECOG) study E3200[ J].Pro Am Soc Clin Oncol,2005,23:1s Abstr 2.
3Sandler AB,Gray R,Brahmer J,et al.Randomized phase Ⅱ/Ⅲ trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab in patients with advanced non-squamous non-small cell lung cancer (NSCLC):An Eastern Cooperative Oncology Group (ECOG) trial-E4599 [ J].Pro Am Soc Clin Oncol,2005,23:2s LBA4.
4Half E,Broaddus R,Danenberg KD,et al.HER-2 receptor expression,localization,and activation in colorectal cancer cell lines and human tumors [ J ].Int J Cancer,2004,108:540-548.
5Sekharam M,Zhao H,Sun M,et al.Insulin-like growth factor 1receptor enhances invasion and induces resistance to apoptosis of colon cancer cells through the Akt/Bcl-x(L) pathway[J].Cancer Res,2003,63:7708-7716.
6Chun YJ,Park S,Yang SA,et al.Activation of Fas receptor modulates cytochrome P450 3A4 expression in human colon carcinoma cells[ J].Toxicol Lett,2003,146:75-81.
7Ohana G,Bar-Yehuda S,Arich A,et al.Inhibition of primary colon carcinoma growth and liver metastasis by the A3 adenosine receptor agonist CF101 [ J].Br J Cancer,2003,89:1552-1558.
8Hainsworth JD,Sosman JA,Spigel DR,et al.Phase Ⅱ trial of bevacizumab and erlotinib in patients with metastatic renal carcinoma(RCC) [ J].Proc Am Soc Clin Onco1,2004,22:382s(abstr 4502).
9Motzer RJ,Rini BI,Michaelson MD,et al.SU0 11248,a novel tyrosine kinase inhibitor,shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma:results of a phase 2 trial[J].Proc Am Soc Clin 0ncol,2004,22:382s (abstr 4500).
10Drach J,Kaufmann H,Woehrer S,et al.Durable remissions after rituximab plus thalidomide for relapsed/refractory mantle cell lymphoma[ J].Proc Am Soc Clin Oncol,2004,22:578s (abstr 6583).
